Astrazeneca

FromAstraZeneca ([email protected])
Subject (46)Imfinzi improved pCR in resectable lung cancer
Preheader (144)Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN Phase III trial in resectable non-small cell lung cancer
Typography
Arial
Colors
Text Analysis
Body Words230
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px806 px
X-Spam Score-0.5
Preheader OptimizedNo
Timing
Day of WeekWednesday
TimeEarly Morning

Imfinzi improved pCR in resectable lung cancer

Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN Phase III trial in resectable non-small cell lung cancer
Imfinzi improved pCR in resectable lung cancer